Aurobindo arm CuraTeQ reports positive Phase 3 results for allergy drug BP11

Aurobindo Pharma unit CuraTeQ reports positive Phase 3 data for Xolair biosimilar BP11 in chronic spontaneous urticaria, plans EMA and FDA filings by end of Q2 2026

Leave a Reply

Your email address will not be published. Required fields are marked *